Teleflex (NYSE:TFX) Stock Price Up 3.8% Following Analyst Upgrade

30 Sep 2026, 06:22 by Sarita Garza · The Markets Daily

Teleflex Incorporated (NYSE:TFX – Get Free Report)’s stock price shot up 3.8% during trading on Monday after Bank of America upgraded the stock from a neutral rating to a buy rating. Bank of America now has a $158.00 price target on the stock, up from their previous price target of $145.00. Teleflex traded as high as $126.46 and last traded at $126.7310. Approximately 510,016 shares traded hands during mid-day trading, a decline of 34% from the average daily volume of 778,157 shares. The stock had previously closed at $122.07.

TFX has been the subject of several other reports. UBS Group increased their price objective on Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Mizuho increased their target price on shares of Teleflex from $140.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Piper Sandler reissued an “overweight” rating and set a $169.00 price target (up from $160.00) on shares of Teleflex in a research report on Friday, August 7th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a report on Monday, September 21st. Finally, Zacks Research raised shares of Teleflex from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teleflex presently has a consensus rating of “Moderate Buy” and a consensus price target of $155.20.

View Our Latest Research Report on Teleflex

More Teleflex News

Here are the key news stories impacting Teleflex this week:

Positive Sentiment: Bank of America upgraded Teleflex to Buy from Neutral and raised its price target to $158 from $145. The firm cited stronger growth prospects, new leadership and the potential for a 2027 re-rating as the key remaining medical-technology businesses become more focused. BofA Upgrades Teleflex to Buy From Neutral
Positive Sentiment: Teleflex reported peer-reviewed data showing its Arrowg+ard™ catheter technology was associated with a 70% lower hazard of central line-associated bloodstream infections. The findings could support adoption of the company’s catheter products and strengthen its competitive position in infection prevention. Teleflex Arrowg+ard Study
Positive Sentiment: The completed $1.5 billion OEM business sale improves financial flexibility. Management plans to use proceeds for approximately $800 million of debt reduction and to complete a $1 billion share-repurchase authorization, which could reduce leverage and support per-share earnings.
Neutral Sentiment: Analysts and market coverage continue to frame 2026 as a transition year, with improved earnings power expected in 2027. Teleflex’s latest quarterly results exceeded estimates, but reported earnings were well below the prior year, leaving investors focused on execution and the pace of recovery.
Negative Sentiment: The stock’s recent rally may have prompted profit-taking, while uncertainty around leadership changes, debt management and the timing of post-divestiture growth can limit near-term upside. Teleflex also maintains full-year 2026 adjusted EPS guidance of $6.90–$7.20, below some analysts’ consensus expectations.

Institutional Trading of Teleflex

Several hedge funds and other institutional investors have recently modified their holdings of TFX. BlackRock Inc. purchased a new stake in shares of Teleflex during the 2nd quarter valued at approximately $688,537,000. Jupiter Topco LLC bought a new position in Teleflex in the 2nd quarter worth about $550,456,000. Janus Henderson Group PLC grew its holdings in Teleflex by 2.0% during the 4th quarter. Janus Henderson Group PLC now owns 4,246,112 shares of the medical technology company’s stock valued at $518,196,000 after buying an additional 84,754 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Teleflex by 10.6% during the fourth quarter. Geode Capital Management LLC now owns 985,684 shares of the medical technology company’s stock valued at $120,312,000 after buying an additional 94,679 shares during the period. Finally, Irenic Capital Management LP purchased a new stake in shares of Teleflex in the first quarter worth about $104,061,000. Institutional investors own 95.62% of the company’s stock.

Teleflex Price Performance

The business’s 50-day moving average price is $133.70 and its 200 day moving average price is $128.86. The company has a market capitalization of $5.34 billion, a P/E ratio of -5.41, a price-to-earnings-growth ratio of 0.85 and a beta of 0.82. The company has a quick ratio of 2.12, a current ratio of 2.60 and a debt-to-equity ratio of 0.94.

Teleflex (NYSE:TFX – Get Free Report) last released its earnings results on Thursday, August 6th. The medical technology company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.28 by $0.48. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The company had revenue of $570.33 million for the quarter, compared to analyst estimates of $559.59 million. During the same quarter last year, the firm earned $3.73 EPS. The firm’s quarterly revenue was up 28.9% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Analysts anticipate that Teleflex Incorporated will post 7.26 EPS for the current fiscal year.

Teleflex Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Friday, August 14th. Teleflex’s dividend payout ratio is -5.84%.

About Teleflex

(Get Free Report)

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, clinicians and other health care providers. Its products are designed to support procedures in areas including vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgery and urology.